Trial intelligence / Profile preview

Idelalisib plus bendamustine and rituximab in previously treated chronic lymphocytic leukemia

2011-006292-20Phase 3Completed

Sponsor
Gilead Sciences
Start
May 2012
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of idelalisib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Gilead Sciences. Started May 2012; status: completed.

02

Drugs

idelalisib
03

Conditions

chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Beyond the preview

Go deeper on 2011-006292-20.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2011-006292-20.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call